TrialCancer research and treatment2023

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Hana Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.